Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer

This study has been completed.
Information provided by (Responsible Party):
Vassilis Georgoulias, MD, University Hospital of Crete Identifier:
First received: May 29, 2008
Last updated: September 25, 2015
Last verified: September 2015
This study will evaluate the efficacy of FOLOFOXIRI plus Cetuximab combination in young patients with good performance status with unresectable metastatic colorectal cancer.

Condition Intervention Phase
Metastatic Colorectal Cancer
Drug: Irinotecan
Drug: Leukovorin
Drug: Oxaliplatin
Drug: Cetuximab
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Triplet Combination With Irinotecan Plus Oxaliplatin,Continuous Infusion 5-Fluorouracil And Leucovorin Plus Cetuximab As First Line Treatment In Metastatic Colorectal Cancer. A Pilot Phase II Trial

Resource links provided by NLM:

Further study details as provided by University Hospital of Crete:

Primary Outcome Measures:
  • Objective Response Rate [ Time Frame: 2 months ]

Secondary Outcome Measures:
  • Resectability rates [ Time Frame: Resectability at the end of treatment (4 or 6 months from the entry to the study) ]
  • Time to Tumor Progression [ Time Frame: 1 year ]
  • Overall Survival [ Time Frame: 1 year ]
  • Toxicity profile [ Time Frame: Toxicity assessment on each chemotherapy cycles (every 15 days) ]
  • Pharmacogenomic analysis [ Time Frame: During the treatment ]
  • Q-Twist analysis of Quality of life [ Time Frame: Quality of life assessment every 8 weeks ]

Enrollment: 30
Study Start Date: July 2007
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: Irinotecan
Irinotecan will be administered at a dose of 150mg/m2 as a 30 min IV infusion on day 1
Other Names:
  • CPT-11
  • Campto
Drug: Leukovorin
Leukovorin will be administered at a dose of 200mg/m2 as a 2-hour IV infusion on days 2 and 3
Other Name: LV
Drug: Oxaliplatin
Oxaliplatin will be administered on day 2 at the dose of 65mg/m2 as a 2-hours IV
Other Names:
  • LoHP
  • Eloxatin
5-FLUOROURACIL at the dose of 400mg/m2 as IV bolus and then, 600mg/m2 as a 22-hour continuous IV infusion, on days 2 and 3
Other Name: 5-FU
Drug: Cetuximab
Cetuximab will be administered at the dose of 500mg/m2 as a 2-hour infusion on day 1 at least one hour before chemotherapy
Other Name: Erbitux

Detailed Description:
The combination of FOLFOXIRI plus cetuximab is reasonable safe regimen especially for patients with good performance status. The estimated benefit from the combination is greater than the possible risk, especially for the patients who will become resectable after treatment. It will be extremely interesting to evaluate the resectability rate of this specific group of patient with good performance status and unresectable disease when they are treated with all active chemotherapeutic agents and cetuximab

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with histologically proven metastatic adenocarcinoma of the colon or rectum
  • Previous chemotherapy for metastatic disease not allowed. Patients who received prior adjuvant 5-FU-based chemotherapy are eligible if they have remained free of disease for at least 6 months after the completion of adjuvant therapy
  • Patients with operable metastatic disease are excluded from the study
  • Age 18-70 years
  • Performance status (ECOG) 0-1
  • At least one bidimensionally measurable lesion of >= 2cm
  • Life expectancy of at least 6 months
  • Adequate hematologic parameters (absolute neutrophil count >= 1.5x109/L and platelets >=100x109/L)
  • Creatinine and total bilirubin < 1.25 times the upper limit of normal
  • Aspartate and alanine aminotransferase < 3.0 times the upper limit of normal (<5 times in case of liver mets)

Exclusion Criteria:

  • Absence of active infection or malnutrition (loss of more than 20% of the body weight)
  • No history of a second primary tumor other than non-melanoma skin cancer or in situ cervical carcinoma. curatively treated
  • Patients treated with palliative radiotherapy had to have measurable metastatic disease outside the irradiation fields.
  • Patients with severe cardiac dysfunction, liver metastases involving more than 50% of the liver parenchyma, chronic diarrhea, or prior irradiation affecting more than 30% of the active bone marrow are excluded.
  • All patients will have to sign written informed consent in order to participate in the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00689624

University Hospital of Crete
Heraklion, Greece
Sponsors and Collaborators
University Hospital of Crete
Principal Investigator: John Souglakos, MD University Hospital of Crete
  More Information

Responsible Party: Vassilis Georgoulias, MD, MD, University Hospital of Crete Identifier: NCT00689624     History of Changes
Other Study ID Numbers: CT/06.21
Study First Received: May 29, 2008
Last Updated: September 25, 2015

Keywords provided by University Hospital of Crete:
Colorectal Cancer

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on April 28, 2017